HRT and Blood Clot Risk: Does the Delivery Method Actually Matter?

Estrogen influences the liver's production of several proteins involved in blood clotting, including clotting factors and proteins that normally keep clotting in check. When estrogen is taken orally, it travels from the digestive tract directly to the liver before reaching the rest of the body — a process called first-pass metabolism. This concentrated liver exposure boosts production of clotting factors more than the same dose delivered another way, tipping the body's clotting balance slightly toward being more clot-prone. This is the same basic mechanism, incidentally, that made older combined oral contraceptive pills carry a recognized clot risk decades before menopausal HRT research caught up to the same question. It's worth being clear that this is a relative risk increase on a background of naturally low absolute risk in most healthy women — not a signal that clots are a common or expected side effect of HRT.

The research on this is unusually consistent for an area of women's health that often has conflicting studies. The ESTHER study, a case-control study led by Scarabin and published in The Lancet, was among the first to show clearly that transdermal estrogen was not associated with an increased risk of venous thromboembolism (VTE — blood clots typically in the legs or lungs), while oral estrogen was. A much larger UK cohort study by Vinogradova and colleagues, published in the BMJ in 2019 and drawing on over a decade of primary care records, confirmed this pattern at scale: oral estrogen was associated with roughly double the risk of VTE compared to non-users, while transdermal estrogen showed no meaningful increase in risk at all. This is now reflected in guidance from the Menopause Society (formerly NAMS) and similar bodies, which note that transdermal routes are preferred for women who have additional risk factors for clotting, precisely because the data so consistently separates the two delivery methods on this specific outcome.

For women with a uterus who need a progestogen alongside estrogen to protect the uterine lining, the choice of progestogen appears to matter for clot risk independent of the estrogen route. The French E3N cohort study, led by Canonico and published across several papers, found that micronized progesterone (a bioidentical form) was associated with a lower clot risk than older synthetic progestins like medroxyprogesterone acetate, when combined with estrogen. This doesn't mean synthetic progestins are unsafe for most women, but it's a genuine factor worth discussing if clot risk is a specific concern for you — alongside the broader question of [bioidentical versus synthetic hormones](/blog/bioidentical-vs-synthetic-hrt-truth-about-difference), which involves more than just this one outcome. Combination formulations and delivery methods vary in how they pair estrogen and progestogen, so this is a genuinely individualized conversation rather than a one-size answer.

Route matters, but it's not the only factor — and for some women, personal risk factors matter more than the delivery method itself. Risk is meaningfully higher with obesity, active smoking, a personal history of a prior blood clot, a family history of clotting at a young age, prolonged immobility (such as after surgery or on a long flight), and inherited clotting disorders like Factor V Leiden, which a portion of the population carries without knowing it. Age also plays a role, with risk rising somewhat as women get further from their final period, which is part of why the timing of when you [start HRT](/blog/when-to-start-hrt-timing-and-the-window-of-opportunity) is discussed alongside route and dose. For women with several of these risk factors, a doctor may recommend transdermal estrogen specifically, or in some cases advise against systemic HRT altogether in favor of non-hormonal or local options.

Relative risk numbers like 'doubled' can sound alarming without context, so it helps to translate them into real numbers. Blood clots are uncommon in healthy women in their 40s and early 50s to begin with — background rates are typically in the range of 1 to 2 per 1,000 women per year, and even a doubling on oral estrogen moves that to roughly 2 to 4 per 1,000 per year, meaning the large majority of women taking oral HRT will never experience a clot. This is a genuinely different risk conversation than, for example, the [WHI data on HRT and breast cancer risk](/blog/hrt-and-breast-cancer-risk-what-the-whi-data-actually-shows), which involves its own separate set of numbers and considerations. The point of understanding absolute risk isn't to dismiss the concern, but to make an informed decision rather than an anxious one — for most healthy women without additional risk factors, either route remains a reasonable option, and transdermal simply offers a further margin of safety for those who want it or need it.

A useful starting question is simply: 'Given my personal and family health history, would transdermal or oral estrogen make more sense for me?' Bring up any personal or family history of blood clots, whether you smoke, your current weight, and any upcoming surgery or travel that involves prolonged immobility, since all of these shift the calculation. It's also worth asking specifically which progestogen is being prescribed and why, given the E3N cohort findings on micronized progesterone. If you're also using a GLP-1 medication, mention that too — while GLP-1s themselves aren't linked to increased clot risk, your prescriber will want the full picture of your current medications and metabolic health when making a recommendation, and coordinating between your menopause and weight-loss care is generally a good habit regardless of what you decide about HRT.

Deciding between oral and transdermal HRT — or whether to start HRT at all — depends on your full health picture, not just one risk factor in isolation. If you want to think through your own situation before your next appointment, that's a good place to start.